Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

Nicolas Girard, MD, Institut Curie
Videos
PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
10/23/2023
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology

Advertisement

News
Patritumab Deruxtecan for Patients With Previously Treated, EGFR-Mutated Non-Small Cell Lung Cancer
10/18/2023
Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.
Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.
Results from the phase 2...
10/18/2023
Oncology
News
Amivantamab Plus Chemotherapy Provides PFS Benefit in EGFR-Mutated NSCLC
09/11/2023
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen...
09/11/2023
Oncology
News
Amivantamab Plus Chemotherapy Provides PFS Benefit in EGFR-Mutated NSCLC
09/11/2023
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.
According to Janssen...
09/11/2023
Oncology

Advertisement

News
Lazertinib as Another First-Line Option for Patients With EGFR-Mutated, Advanced NSCLC
08/02/2023
According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.
According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.
According to results from the...
08/02/2023
Oncology
News
Zipalertinib Displayed Promising Preliminary Antitumor Activity Among Patients With EGFR-Mutant NSCLC
07/24/2023
According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.
According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.
According to results of a phase...
07/24/2023
Oncology
News
Zipalertinib Displayed Promising Preliminary Antitumor Activity Among Patients With EGFR-Mutant NSCLC
07/24/2023
According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.
According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.
According to results of a phase...
07/24/2023
Oncology

Advertisement

News
Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation
07/20/2023
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation
07/20/2023
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
Adjuvant Osimertinib Significantly Improved Overall Survival Among Patients With EGFR-Mutated NSCLC
07/10/2023
According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.
According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.
According to final analysis...
07/10/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use